1. [Patient's beliefs about oral targeted therapies and impact on drug adherence in lung cancer: A pilot prospective study].
- Author
-
Torrecillas S, Perrot E, Gérinière L, Locatelli-Sanchez M, Laffay L, Souquet PJ, and Couraud S
- Subjects
- Administration, Oral, Chemotherapy, Adjuvant, Crizotinib, Erlotinib Hydrochloride administration & dosage, Female, Humans, Lung Neoplasms epidemiology, Lung Neoplasms psychology, Male, Pilot Projects, Prospective Studies, Protein Kinase Inhibitors administration & dosage, Pyrazoles administration & dosage, Pyridines administration & dosage, Surveys and Questionnaires, Antineoplastic Agents administration & dosage, Culture, Lung Neoplasms drug therapy, Medication Adherence psychology, Medication Adherence statistics & numerical data, Molecular Targeted Therapy psychology
- Abstract
Introduction: Oral targeted therapies are a new option for lung cancer treatment. However, patient's belief about these drugs - which may interact with adherence - is poorly known in this setting., Method: Our study is a pilot prospective unicentric study. Inclusion criteria were: to have been diagnosed with a lung cancer; and to be prescribed with an oral targeted therapy in second line or more. The main objective was to assess patient's specific (SB) and general beliefs (GB) about these drugs according to the Beliefs about Medicines Questionnaire (BMQ). The declared adherence was assessed with the Morisky's test. All included patients underwent a semi-structured interview with a psychologist., Results: Fifthteen patients were included: 12 underwent erlotinib treatment and 3 a crizotinib treatment. The mean score (±standard deviation) at BMQ was 54/85 (±6) overall; 34/50 (±5) for specific belief and 19/35 (±3) for general belief about drugs. During interview, 47% believed in efficacy of targeted oral therapy; 93% reported concerns about their drug; 80% considered that the information given by the physician about the drug was comprehensive; but 40% still required additional information about it. The mean score at Morisky's test was 3/4 (±2) and 53% reported to have forgotten at least once their antineoplastic drug. No correlation was found between belief and adherence., Conclusion: Belief about t anti-cancer targeted oral therapy is relatively fair but adherence is moderate in this pilot study. Interview shows the need for additional information about the prescribed drug., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF